New drug trial targets aggressive pancreatic Cancer's genetic weakness
NCT ID NCT07283705
Summary
This study is testing if adding an experimental drug called BMS-986504 to standard chemotherapy helps control pancreatic cancer in people whose tumors have a specific genetic change called an MTAP deletion. It aims to see if the combination is safe and can slow cancer growth or improve surgical outcomes. The trial is currently suspended and was enrolling about 60 adults with different stages of this specific type of pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE 2 STUDY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.